THE EFFCT OF METFORMIN USE ON PROGNOSIS IN PANCREATIC CANCER PATIENTS
Küçük Resim Yok
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Carbone Editore
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: Several clinical studies have shown the effect of mefformine on survival in pancreatic cancer. We aimed to evaluate whether the use of mefformin in diabetic pancreatic cancer patients provides a survival advantage or not. Methods: The data of 467 pancreatic adenocarcinoma patients diagnosed between 2003 and 2012 from five centers were analyzed, retrospectively. The groups were pancreatic cancer patients with diabetes who use metfonnin, who don't use metfornzin and non-diabetics. Results: Median overall survival was 8 months for the whole cohort, and 8 months for the group of non-diabetic patients. Overall survival was 8 months for the diabetic patients who use metfonnin whereas 10 months for the patients who do not use metformin. There was no statistically significant survival difference between the groups (p:0,76). Conclusion: Our study did not support clinical benefit of metformin in diabetic pancreatic cancer patients.
Açıklama
Anahtar Kelimeler
Pancreatic Cancer, Diabetes Mellitus, Metformine
Kaynak
Acta Medica Mediterranea
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
30
Sayı
2
